Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.

@article{Dunn1999AbciximabAP,
  title={Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.},
  author={Christopher J. Dunn and Rachel H. Foster},
  journal={PharmacoEconomics},
  year={1999},
  volume={16 6},
  pages={711-41}
}
UNLABELLED Abciximab is a monoclonal antibody fragment that inhibits platelet aggregation through antagonism of glycoprotein IIb/IIIa. The drug is used in conjunction with heparin and aspirin to prevent ischaemic complications associated with percutaneous coronary revascularisation in patients with coronary heart disease. Large and well designed clinical studies have shown abciximab, as an adjunct to aspirin and heparin, to reduce by around one-third to one-half the incidence of ischaemic… CONTINUE READING